<DOC>
	<DOCNO>NCT02952040</DOCNO>
	<brief_summary>The objective study evaluate effect lanthanum carbonate hydrate pharmacokinetics ( PK ) ASP1517 non-elderly healthy male subject .</brief_summary>
	<brief_title>A Drug Interaction Study Evaluate Pharmacokinetics ASP1517 Lanthanum Carbonate Hydrate</brief_title>
	<detailed_description />
	<criteria>Body weight ( screen ) : ≥50.0 kg &lt; 80.0 kg Bodymass index ( screen ) : ≥17.6 &lt; 26.4 kg/m2 [ Bodymass index = Body weight ( kg ) / ( Height ( ) ) 2 ] Subject must agree use contraception consist two establish form specify starting time inform consent continue throughout treatment period 84 day last administration ASP1517 . Subject must agree donate sperm start time informed consent continue throughout 84 day last administration ASP1517 . Received schedule receive investigational drug clinical trial postmarketing study within 120 day screen period screen hospital admission day Period 1 . Received scheduled receive medication ( include overthecounter drug ) supplement within 7 day hospital admission day Period 1 . Deviates normal range blood pressure , pulse rate , body temperature standard 12lead electrocardiogram screening hospital admission day Period 1 . Meets follow criterion laboratory test screen hospital admission day Period 1 . Normal range test specify study site test/assay organization use normal range study . Concurrent previous drug allergy . Development ( ) upper gastrointestinal symptom ( ) within 7 day hospital admission day Period 1 . Concurrent previous hepatic disease , heart disease , respiratory disease , peritoneum inflammation . A history abdominal surgery , digestive tract excision . Concurrent previous renal disease , endocrine disease , cerebrovascular disorder , malignant tumor , retinal neovascular lesion . Previous use hypoxia inducible factorprolyl hydroxylase inhibitor ( HIFPHI ) ASP1517 ( FG4592 ) , YM311 ( FG2216 ) , erythropoietin product lanthanum carbonate hydrate . Excessive alcohol smoking habit .</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>44 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>ASP1517</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Drug-drug interaction</keyword>
</DOC>